Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
暂无分享，去创建一个
R. Greil | J. Slotta-Huspenina | E. Van Cutsem | F. Lordick | M. Alsina | R. Hofheinz | A. Vogel | M. Lutz | W. Eisterer | S. Al-Batran | T. Ettrich | S. Lorenzen | A. Schad | P. Thuss-Patience | B. Brenner | M. Moehler | L. Mueller | A. Maderer | J. Meiler | K. Borchert | M. Alsina | E. Cutsem | Florian Lordick | R. D. Hofheinz | Arndt Vogel | T. J. Ettrich | T. Ettrich | R. Hofheinz